ijms-logo

Journal Browser

Journal Browser

Molecular Research in Viral Hepatitis and Liver Cancer

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 30 May 2024 | Viewed by 691

Special Issue Editor

Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
Interests: hepatocellular carcinoma; viral hepatitis; liver cancer

Special Issue Information

Dear Colleagues,

Viral hepatitis (mainly hepatitis B, C, and D) has continued to be a global threat. New mechanisms in the pathogenesis of inducing liver diseases have been discovered over the past few decades. One of the major complications of viral hepatitis is hepatocellular carcinoma (HCC), and its mortality rates are rapidly increasing worldwide. Cirrhosis, a chronic complication of viral hepatitis, is also known to be a major risk factor for HCC. Although hepatitis B vaccination and antiviral therapy for hepatitis B and C are effective the for primary prevention of HCCs, unmet clinical needs require further in-depth studies centred around molecular mechanisms. Primary HCC may arise out of synergy between chronic viral infection and other carcinogenic stimuli that induce increased hepatic mitotic activity. Common mechanisms shared by HBV, HCV, and HDV in causing liver cancer include persistent liver inflammation with an impaired anti-viral immune response, viral protein-mediated oxidative stress, and dysregulated cellular signaling pathways. In this Special Issue, investigators provide further evidence in this important field.

Prof. Dr. Teh-Ia Huo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatitis B
  • hepatitis C
  • hepatitis D
  • hepatocellular carcinoma

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 993 KiB  
Article
Albumin-Based Liver Reserve Models vs. MELD 3.0 in Prognostic Prediction for Hepatocellular Carcinoma Patients with Renal Insufficiency
Int. J. Mol. Sci. 2023, 24(23), 16987; https://doi.org/10.3390/ijms242316987 - 30 Nov 2023
Viewed by 547
Abstract
The severity of liver functional reserve is an important prognostic predictor in hepatocellular carcinoma (HCC). The albumin–bilirubin (ALBI), easy (EZ)-ALBI, platelet-albumin–bilirubin (PALBI), platelet–albumin (PAL) score, and MELD 3.0 score are used to evaluate the severity of liver dysfunction. However, their prognostic role in [...] Read more.
The severity of liver functional reserve is an important prognostic predictor in hepatocellular carcinoma (HCC). The albumin–bilirubin (ALBI), easy (EZ)-ALBI, platelet-albumin–bilirubin (PALBI), platelet–albumin (PAL) score, and MELD 3.0 score are used to evaluate the severity of liver dysfunction. However, their prognostic role in HCC patients, specifically with renal insufficiency (RI), is unclear. We aimed to investigate the predictive accuracy of the five models in these patients. A total of 1120 newly diagnosed HCC patients with RI were enrolled. A multivariate Cox proportional analysis was used to identify independent predictors associated with survival. In the Cox model, older age, an α-fetoprotein ≥20 ng/mL, vascular invasion, a medium and high tumor burden score, poor performance status, a higher ALBI grade, an EZ-ALBI grade, a PALBI grade, a PAL grade, and MELD 3.0 score were all independently associated with decreased overall survival (all p < 0.001). Among the five liver reserve models, the ALBI grade is the best surrogate marker to represent liver functional reserve in terms of outcome prediction. The albumin-based liver reserve models (ALBI, EZ-ALBI, PALBI, and PAL) and MELD 3.0 are all feasible prognostic markers to indicate liver injury, specifically in HCC patients with RI. Among them, the ALBI grade is the most robust tool for survival prediction in these patients. Full article
(This article belongs to the Special Issue Molecular Research in Viral Hepatitis and Liver Cancer)
Show Figures

Figure 1

Back to TopTop